$32.1m market cap
$4.59 last close
InMed is a pharmaceutical company focused on developing and manufacturing cannabinoids. Its main pipeline product is INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.
Investment summary
Following the safety and tolerability data from the two Phase I trials in healthy volunteers, INM-755 is moving forward into a Phase II (755-201-EB) trial in up to 20 epidermolysis bullosa (EB) patients with an anticipated treatment duration of 28 days. Regulatory applications are expected to be filed in several countries in Q2 CY21 with enrolment to begin in the second half of the calendar year. Also, the formulation for INM-088 has been finalized with IND-enabling toxicology studies expected to begin in CY21 and filings for human clinical trials to begin in H1 CY22.
Y/E Jun |
Revenue (US$m) |
EBITDA (US$m) |
PBT (US$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2019A | 0.0 | (9.4) | (9.2) | (177.47) | N/A | N/A |
| 2020A | 0.0 | (9.0) | (9.0) | (172.80) | N/A | N/A |
| 2021E | 0.0 | (8.7) | (9.1) | (132.97) | N/A | N/A |
| 2022E | 0.0 | (9.5) | (10.5) | (123.74) | N/A | N/A |
Industry outlook
The market for cannabinoids, whether FDA-approved, medical or recreational, is growing at a fantastic rate. Legal cannabis sales in the US alone were around US$7.5bn in 2017 and we expect them to grow to US$28bn by 2023.
Last updated on 23/02/2021
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (US$m) | 9.1 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Bruce Colwill | CFO |
| Eric Adams | President & CEO |
